London, UK, 13 January 2012 Sinclair IS Pharma (AIM:SPH.L) ("Sinclair IS" or the "Group"), the international specialty pharma company, announces a trading update for the six months ended 31 December 2011 ahead of its interim results which will be announced on 23 February 2012.
• Revenue for the first half grew by more than 65% to reach approximately £23.4 million
• Like-for-like revenue growth of 9% for the period
• Sinclair IS profitable at the EBITDA level for the first half
• Continued focus on a smaller number of key brands, which management believes will be central to the Company's future success, including Flammazine and Kelo-cote
• Disposal of non-core Mysoline and acquisition ofex-US rights for Kelo-cote®
Revenues for the six months ended 31 December 2011 were approximately £23.4 million, compared to £14.1 million for the same period last year, an increase in excess of 65%, and in-line with market expectations despite difficult trading conditions in our core European markets.
Like-for-like revenues (excluding product acquisitions and disposals, licence fees and currency fluctuations) increased by 9% over the period driven by the focus on a smaller number of key brands and the initial launches by Invida of Sinclair IS products across the Asia-Pacific region. Revenues from the Flamma franchise, Kelo-cote, Atopiclair and Bio-Taches all grew strongly in the period. Unsurprisingly, pharmaceutical market volumes and pricing remain under significant pressure across European markets; we have also seen de-stocking by wholesalers in a number of our European operations during the period. While de-stocking has held back like for like revenue growth in the period we are encouraged to see prescription data which shows that underlying demand for our products, so far, remains strong.
The first half year is the maiden reporting period for the enlarged Sinclair IS group following the merger with IS Pharma. The Group will report a small profit at the EBITDA level for the period compared with a loss of £1.3 million reported for the same period last year.
During the first half Invida, the Company's partner for the Asia Pacific region, successfully launched two of Sinclair IS's leading dermatology brands; Atopiclair for atopic dermatitis (into seven markets) and Papulex for acne (into six markets). Invida has seen good demand for these products and initial sales have been encouraging. Invida will launch these products into other territories in the region during the second half.
In-line with the Group's strategy to complement its proprietary sales infrastructure with selected co-promotion partners, Sinclair IS entered into exclusive promotion agreements with Therabel and Norgine in the first half, to market and commercialise Xclair, the Group's treatment for radiation dermatitis, in France and Spain respectively.
As part of its strategy to focus on fewer, bigger brands during the period the Group disposed of Mysoline, a non-core product acquired from the merger with IS Pharma, for £11.1 million and used the cash to part fund the acquisition of Advanced Bio-Technologies, Inc. The acquisition gave Sinclair IS global ownership, excluding the US, to scar prevention and treatment product Kelo-cote®, a well-established, potentially high growth product, which is now Sinclair IS' second largest brand.
Chris Spooner, CEO of Sinclair IS, commented: "I am pleased with the strong performance of the Company during the first half. We have continued to deliver on our strategy to focus on fewer, bigger brands and build strong strategic partnerships. We are making good progress to becoming a high growth, self-sustaining international specialty pharma business. The first wave of launches by Invida has been very promising and we continue to focus on striking additional multi-country, multi-product deals in emerging markets during the second half."
For further information please contact:
Sinclair IS Pharma plc Tel: +44 (0) 20 7467 6920
Jefferies International Limited (NOMAD and Broker) Tel: +44 (0) 20 7029 8000
Sinclair IS Pharma is an international specialty pharmaceutical company focused on treatments in dermatology, wound care, oncology support and critical care through advanced surface technology and innovative delivery systems. The Company has a growing sales and marketing operation with a direct sales presence in the top five European markets and an extensive marketing partner network across selected developed and emerging markets.
"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety offactors.
This information is provided by RNS
The company news service from the London Stock Exchange
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.